# GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors

Source: https://onco.cc/trials/nct06265025/  
OnCo record `nct06265025` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Pembrolizumab in melanoma and colorectal cancer, run by GeneMedicine Co., Ltd., now recruiting.

## Summary

GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT06265025 by GeneMedicine Co., Ltd., with 125 participants planned, started 2024-02-20 and due to reach its primary completion in 2025-05-30. Interventions recorded: GM103 (Part A), GM103 (Part B), GM103 and Pembrolizumab (Part C). Conditions listed: Head and Neck Cancer, Malignant Melanoma, Colorectal Cancer, Renal Cell Carcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06265025
- Phase: 1/2
- Setting: A Phase I/II, Open-label, Dose-escalation With Expansion Study of GM103 Via Intratumoral Injection, Alone and in Combination With Pembrolizumab in Adult Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors
- Sponsor: GeneMedicine Co., Ltd.
- Enrolled: 125

## Sources

- ClinicalTrials.gov NCT06265025: https://clinicaltrials.gov/study/NCT06265025

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Melanoma](https://onco.cc/cancers/melanoma/), [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)

---
JSON: https://onco.cc/api/v1/entities/nct06265025.json